BioSpace News Archive

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31 st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

First patent issued for the use of lenzilumab to reduce non-GM-CSF cytokines/chemokines that contribute to immunotherapy-related toxicity Second patent issued for the use of lenzilumab to improve the efficacy and durability of immunotherapy

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format.

Company will provide business updates during the earnings call and release investor day video segments on Company website

- Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models - - Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines -

- RLYB212: A Novel Monoclonal HPA-1a Antibody for the Prevention of a Potentially Life-Threatening Rare Disease that Impacts Fetuses and Newborns – - RLYB116: A Novel Small Protein Inhibitor of Complement C5 for the Treatment of Patients with Severe and Rare Diseases of Complement Dysregulation -

– SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis has achieved target enrollment; topline data expected in mid-2021 – – Continued enrollment in SER-109 open label study in recurrent C. difficile infection to support planned BLA filing; potential to be first FDA-approved microbiome therapeutic – – Conference call at 8:30 a.m. ET today –

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 9, 2021, at 8:30 a.m. ET to review its full year 2020 financial results and provide an update on the company.

- Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 - - ANNOVERA ® net product revenue increased 42% for 4Q20 compared to 3Q20 - - Financing Agreement amended to update minimum net revenue covenants for remainder of loan; Company to pay down $50 million in debt -

AVEO Oncology announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.